Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to Issue Quarterly Dividend of $0.94

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Tuesday, November 3rd. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share by the biopharmaceutical company on Thursday, December 3rd. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th.

Regeneron Pharmaceuticals has a payout ratio of 9.6% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Regeneron Pharmaceuticals to earn $53.12 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 7.1%.

Regeneron Pharmaceuticals Trading Up 1.3%

Shares of REGN stock opened at $973.36 on Wednesday. Regeneron Pharmaceuticals has a 1-year low of $591.52 and a 1-year high of $975.49. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The stock has a market cap of $100.22 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 1.51 and a beta of 0.10. The stock has a 50-day moving average of $798.74 and a 200-day moving average of $740.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same period in the previous year, the firm earned $11.83 earnings per share. The firm’s quarterly revenue was up 36.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.